Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Afinitor

- PMLiVE

NHS England reveals COVID-19 autumn booster campaign plans

The rollout will begin in early September and see Moderna’s next generation bivalent COVID-19 vaccine offered where appropriate

- PMLiVE

NHS bowel cancer checks reach record-high following death of Dame Deborah James

Between May and July 2022, over 170,500 people were referred for suspected lower gastro-intestinal cancers – up over 30,000 compared to the same period last year

- PMLiVE

NHS England outlines measures to boost capacity ahead of substantial winter pressures

The package of measures includes creating the equivalent of 7,000 additional hospital beds

- PMLiVE

Over 47,000 stroke patients to miss out on ‘game-changing’ treatment, the Stroke Association warns

This year, NHS England failed to reach its original target to make mechanical thrombectomy available to all suitable patients

- PMLiVE

Shionogi Europe and NHS England agree on antibiotic subscription model

The antibiotic Fetcroja, along with Zavicefta, will be made available as an option to help address antimicrobial resistance

- PMLiVE

EFPIA-EURORDIS joint statement published on patient access to medicines for rare diseases

The statement contains a series of proposals to improve the lives of people living with rare diseases by addressing access barriers to transformative medicines

- PMLiVE

NHS England launches pilot programme for high street pharmacy referrals

The scheme aims to diagnose more early stage cancers without the need for a GP appointment

- PMLiVE

UK government allocates up to £680m a year to two funds offering cutting-edge treatments

The new Innovative Medicines Fund will enable patients in England to gain fast-track access to drug treatments

- PMLiVE

Novo Nordisk and Flagship Pioneering to collaborate on new research programmes

The companies will focus on rare and cardio-metabolic disease areas

- PMLiVE

Nucleus X Consulting – where patient engagement meets strategic consultancy

Nucleus X Consulting consists of an agile team of specialists that combine expertise in all aspects of patient engagement along with strategic consultancy in rare disease and early-phase medical commercialisation.We...

Nucleus Global

Extraordinary lives: advancing change in rare diseases (Part 2)

In support of Rare Disease Day, we’re excited to launch part 2 of our video series; Extraordinary lives: advancing change in rare diseases.Why is raising awareness of rare diseases so...

Lucid Group Communications Limited

- PMLiVE

Nucleus Global launches Nucleus X Consulting, a specialist consultancy with deep expertise in patient engagement, rare disease, and early-phase medical commercialization

Nucleus Global, the largest specialist medical communications network in the world, announces the launch of a new consultancy to add to its family of agencies. Nucleus X Consulting consists of...

Nucleus Global

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links